The association of leptin with dyslipidemia, arterial hypertension and obesity in Kyrgyz (Central Asian nation) population by Erkin Мirrakhimov et al.
Мirrakhimov et al. BMC Research Notes 2014, 7:411
http://www.biomedcentral.com/1756-0500/7/411RESEARCH ARTICLE Open AccessThe association of leptin with dyslipidemia,
arterial hypertension and obesity in Kyrgyz
(Central Asian nation) population
Erkin М Мirrakhimov1,2,3*, Alina S Kerimkulova1, Оlga S Lunegova2, Aibek E Mirrakhimov1, Malik P Nabiev1,
Kseniya V Neronova1, Asiyat A Bayramukova1, Nazira T Alibaeva3 and Nurdin Satarov1Abstract
Background: Leptin, an adipocytokine produced by adipose tissue, along with the traditional cardiometabolic risk
factors, contributes to the development of cardiovascular complications. At the same time, ethnic features of
adipocytokines have been insufficiently investigated, especially among Asians, who have an increased risk of
cardiovascular complications compared with Europeans. Aim of study was to investigate the relationship between
leptin levels and age, gender, anthropometric parameters, lipid parameters, arterial hypertension (AH), and obesity
in the adult population of ethnic Kyrgyz people living in Central Asia.
Results: In total, 322 ethnic Kyrgyz (145 men, 177 women) aged ≥ 30 years were studied. Waist and hip
circumference, body mass index, blood glucose, lipids, leptin, and homeostatic model assessment were measured.
Patients in the upper quartile of leptin levels had high values of BMI, WC, systolic and diastolic blood pressure,
glucose, and HOMA index compared with patients with lower leptin levels. The prevalence of metabolic syndrome
and AH increased with higher levels of leptin. Leptin positively correlated with BMI, WC, triglycerides, and glucose
concentrations in patients of both sexes. According to the multivariate logistic regression analysis, elevated leptin
levels increased by 30 times the risk of obesity in men, regardless of the presence of type 2 diabetes, and 17.7
times in women.
Conclusion: Leptin is associated with general and abdominal obesity, dyslipidemia, and insulin resistance in Kyrgyz
patients.
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High global prevalence of cardiometabolic diseases and
the related mortality stimulated research focused on the
risk factors, one of which is obesity [1-3]. It is well known
that overweight and obese individuals have higher gen-
eral as well as cardiac mortality [4]. Furthermore, obesity
is strongly associated with the development of arterial
hypertension (AH), insulin resistance (IR), type 2 dia-
betes mellitus (DM), atherogenic dyslipidemia, and other
diseases [5].* Correspondence: ermir@infotel.kg
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article, unless otherwise stated.The association between obesity and cardiometabolic
risk factors may be mediated by the ability of adipocytes
to synthesize biologically active substances with hormo-
nal activity [6]. One of these hormones is leptin, which
was identified in 1994 and has attracted the attention of
obesity researchers [7]. Leptin is a 167 amino acid protein
encoded by the obesity (OB) gene and is synthesized and
secreted by adipocytes. In this case, serum leptin concen-
trations reflect the amount of energy reserves stored in
adipose tissue [8]. In addition, leptin plays an important
role in the regulation of feeding behavior and is closely as-
sociated with body mass index (BMI) and AH [9]. Leptin
was shown to be associated with IR and other cardiometa-
bolic risk factors in certain populations [10-12].ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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different impact on metabolic risk factors and develop-
ment of cardiovascular diseases in different ethnic groups
[13]. It was also shown that among Asians, compared with
Europeans, there is a higher incidence of coronary heart
disease (CHD) [14]. In addition, cardiometabolic risk fac-
tors such as type 2 DM, IR, and abdominal obesity are
often identified among Asians [15-17]. This raises the
question of whether ethnicity influences the prevalence of
cardiometabolic risk factors and cardiovascular disease,
which has not been sufficiently studied.
Levels of leptin have never been studied in the ethnic
Kyrgyz population. The purpose of this study was to in-
vestigate the relationship between leptin levels and age,




In 2008, we conducted a pilot cross-sectional study asses-
sing the prevalence of cardiometabolic risk factors among
residents of Kyrgyzstan. That study included 956 subjects
who were later enrolled in the current investigation.
Exclusion criteria were age < 35 and > 70 years, condi-
tions that could potentially alter leptin concentrations such
as prolonged fasting, surgery within 1 month from study
enrollment, advanced chronic diseases (such as chronic
liver disease, chronic kidney disease, systemic autoimmune
disease, congestive heart failure, thyroid disease, etc.),
chronic use of glucocorticosteroids, use of lipid-lowering
medications, patients with DM using insulin, pregnancy
and lactation, chronic alcohol abuse, and people not of a
Kyrgyz ethnic background. Thus, we included 322 ethnic
Kyrgyz (145 men, 177 women), who signed informed con-
sent to participate in the study, which included taking
blood samples that were sent to France for analyses. The
study protocol was approved by the local Ethical Commit-
tee of the National Center of Cardiology and Internal
medicine, named after M.M. Mirrakhimov.
Clinical examinations and laboratory analysis
All participants were examined by a cardiologist. The
examination included taking the presenting complaints,
medical history, physical examination with measurement
of anthropometric parameters (height, weight, waist cir-
cumference [WC], hip circumference [HC], and blood
pressure [BP]). BMI was calculated using the following
formula: BMI = weight (kg)/height (m)2. Obesity was con-
sidered as a BMI ≥30 kg/m2 and overweight as a BMI of
25–29.9 kg/m2 [18]. IR was calculated using the HOMA
index values with the following formula: HOMA= serum
insulin (μIU/ml) × plasma sugar (mmol/L)/22.5. A value
of ≥2.77 was considered to be diagnostic for IR. Meta-
bolic syndrome (MS) was defined according to modifiedATP-III criteria [19]. All included patients filled out the
Finnish Diabetes Association questionnaire to assess the
risk of developing DM [20], which included information on
vegetable consumption (every day or not every day) and
physical activity (more or less than 30 minutes per day).
Blood samples were taken as previously described
[21]. Laboratory tests included blood glucose (fasting),
lipid profile (total cholesterol [TC], triglycerides [TG],
high-density lipoprotein cholesterol [HDL-C], and low-
density lipoprotein cholesterol [LDL-C]). All biochemical
analyses were carried out in Dir adjoint du département
Hommes, Natures, Muséede l'Homme (Paris, France).
Leptin was determined using solid-phase enzyme im-
munoassay (EIA), and insulin by the enzyme-linked im-
munosorbent assay (ELISA)method (Bayer Corp). LDL-C
was calculated by the Friedwald formula [22].
Statistics
Statistical analysis was performed using SPSS 17.0 for
Windows (SPSS, Inc., Chicago, IL). Variables with a nor-
mal distribution are presented as mean ± standard devi-
ation and those with a nonparametric distribution as
median (25th and 75th percentiles). The relationship
between leptin and cardiometabolic risk factors was
examined using Spearman rank order correlation. Ana-
lysis of variance (ANOVA) according to the Kruskal-Wallis
method was used to compare the values (given the non-
parametric distribution of variables). Post-hoc comparisons
were performed by the Mann–Whitney test. Multivariate
logistic regression analysis with stepwise inclusion of the
variables was performed to identify the main factors influ-
encing the development of obesity in the study group.
Serum leptin concentrations were transformed into a nat-
ural logarithm to normalize the asymmetric distribution. A
p-value < 0.05 was considered to be statistically significant.
Results
Clinical characteristics
Clinical characteristics of the patients enrolled in the study
are presented in Table 1. The mean age was 51.7 ±
9.6 years. The prevalence of major cardiovascular risk fac-
tors (obesity, abdominal obesity, type 2 DM, smoking, and
hyperlipidemia) was consistent with their prevalence in
the sample from the primary study that was conducted
in 2008 (please see the subjects section). However, the
prevalence of AH was higher in the current sample
(41.9%) compared with the initial group (36.2%). Never-
theless, systolic and diastolic BP were comparable in the
two populations.
For evaluation of the association between leptin levels
and cardiometabolic risk factors, all participants in
the study were stratified into four groups based on quar-
tiles of leptin (< 2.2, 2.2–4.2, 4.3–6.34, > 6.34 ng/ml for
males; < 8.05, 8.05–13.4, 13.5–19.09, > 19.09 ng/mL for
Table 1 Clinical characteristics of patients
n = 322
Age, years 51,7 ± 9,6
Male, n (%) 145 (45)
Obesity, n (%) 94 (29,2)
BMI, kg/m2 27,4 ± 4,8
АО, n (%) 136 (42,2)
WC, cm 91,2 ± 11,5
HC, cm 101,4 ± 10,3
WC/HC 0,9 ± 0,08
AH, n (%) 135 (41,9)
SBP, mm Hg 135 ± 22
DBP, mm Hg 85 ± 12
Type 2 DM, n (%) 22 (6,8)
Fasting glucose, mmol/l 5,48 (5,1; 5,9)
TC, mmol/l 5,1 ± 1,1
HDL-C, mmol/l 1,1 ± 0,3
LDL-C, mmol/l 3,2 ± 0,9
TG, mmol/l 1,2 (0,9; 1,9)
МС, n (%) 107 (33,2)
Leptin, ng/ml 7,8 (4,0; 14,7)
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groups showed a significant difference in the age of the
men: participants in the in the 4th quartile were younger
(p = 0.02). At the same time, it was observed that patients
in the upper quartile of leptin had high values of BMI,
WC, systolic BP and diastolic BP, glucose, and HOMA
index compared with patients with lower leptin levels.
The prevalence of MS and AH increased with higher
levels of leptin. The above-described pattern was observed
for the women as well, although the age was comparable
in the groups of women. In addition, in contrast to the
men, the groups of women showed no significant differ-
ence in TC, TG, LDL-C, as well as the occurrence of type
2 DM. The last was obviously due to the small number of
patients with diabetes (Table 2).
To study the association of leptin levels with BMI, pa-
tients were stratified into three groups: normal weight
(BMI < 25 kg/m2); overweight (BMI ≥ 25–29.9 kg/m2);
and obese (BMI ≥ 30 kg/m2). Comparative analysis re-
vealed elevated leptin concentrations in men and women
with increasing BMI (p < 0.001; Table 3).
Next, we calculated Spearman correlation coefficients
for leptin and anthropometric parameters, lipid profile,
and blood sugar levels in men and women (Table 4). Lep-
tin positively correlated with BMI, WC, TG, and glucose
concentrations in patients of both sexes. At the same time,
leptin was positively correlated with TC in men, and nega-
tively correlated with HDL-C in women (Table 4).Multivariate logistic regression analysis was performed
to assess the impact of various factors on the develop-
ment of obesity and cardiovascular risk factors. Several
regression models were analyzed, with the presence of
obesity, AH, IR, DM as dependent variables and factors
that may have an impact on their development (leptin,
HDL-C, age, BMI, DM, AH, physical activity [more than
30 or less than 30 minutes a day] and vegetable consump-
tion [every day or not every day]) as independent variables.
According to the analysis, elevated leptin levels in-
creased by 30 times the risk of obesity in men, regardless
of the presence of DM, and 17.7 times in women. In
addition, physical activity of less than 30 minutes a day
in women increased the risk of obesity by 3.2 times. A
similar regression model constructed for AH showed that
leptin levels increased by 2.1 times the risk of hyperten-
sion in men (p = 0.003; odds ratio [OR] 2.1; confidence
interval [CI] 1.3–3.6) and in women (p = 0.01; OR 1.75; CI
1.2–3.8). However, an interconnected influence of leptin
was lost after adjustment for BMI as an independent vari-
able in the regression equation, probably due to obesity.
Elevated levels of leptin also increased by 4.3 times the
risk of IR in men and 6.9 times in women, regardless of
BMI. The regression model for DM showed a trend for
statistical significance (Table 5).
Discussion
Unequal prevalence of cardiovascular disease in different
ethnic groups is characterized by greater occurrence of
cardiometabolic risk factors among Asians compared with
Europeans [14]. Indeed, type 2 DM, IR, and abdominal
obesity are frequently detected among Asians [15-17].
However, the available scientific publications are based
mainly on research among South Asians [14-17]. Kyrgyz
are people living in Central Asia, mainly in the highlands,
with a different ancestral origin. Extrapolation of the re-
sults of the above-mentioned studies to the Kyrgyz ethnic
group is not entirely correct, because there are significant
differences between geographical living conditions and
nutritional factors in the Kyrgyz compared with residents
of South Asia (southern India, Pakistan, and Bangladesh).
In the present study, serum leptin concentrations were
3.1 times higher in women than in men. Similar sexual di-
morphism was found in other studies (the difference
ranged from 2.35 to 4.8 times) [23,24]. Gender differences
in serum leptin concentrations are apparently due to sev-
eral factors: the high content of fat in women [25-27];
structural differences in the hypothalamus [27]; and the
influence of sex hormones. It is thought that androgens
have a suppressive effect on leptin concentrations [27]. In
addition, gender differences in leptin concentrations may
also be affected by differences in body fat distribution.
Central fat distribution is more common in men and per-
ipheral fat distribution in women [28]. WC and HC are
Table 2 Characteristics of patients in association with leptin level*
Men 1 quartile n = 39 2 quartile n = 35 3 quartile n = 35 4 quartile n = 36 p
Age, years 52,5 ± 10,8 56,6 ± 9,6 55 ± 9,6 50,3 ± 8,5† 0,02
BMI kg/m2 22,9 ± 2,3 25,5 ± 2,5## 27,7 ± 2,2##† 29,8 ± 4,1##††§ 0,0001
WC, cm 83,7 ± 8,1 92,7 ± 7,2## 98,9 ± 6,6##† 102,1 ± 11,6##†† 0,0001
AH, n (%) 12 (30,8) 15 (42,9)# 17 (48,6)# 23 (63,9)## 0,0004
SBP, mm Hg 126 ± 18 139 ± 20# 139 ± 20# 148 ± 23## 0,0001
DBP, mm Hg 80 ± 12 84 ± 10 90 ± 12#† 95 ± 14##†† 0,0001
TC, mmol/l 4,7 ± 0,9 5,3 ± 1,3 5,7 ± 1,1# 5,2 ± 1,03 0,004
TG, mmol/l 1,1 (0,8;1,5) 1,8 (1,2;2,4)## 1,5 (1,2;2,6)## 1,7 (1,2;2,4)## 0,000
HDL-C, mmol/l 1,13 ± 0,4 0,9 ± 0,3 1,0 ± 0,3 1,05 ± 0,3 0,4
LDL-C, mmol/l 3,04 ± 0,8 3,4 ± 1,3 3,8 ± 1,04# 3,3 ± 0,8 0,03
Type 2 DM, n (%) 0 (0) 4 (11,4) 6 (17,1) 4 (11,1) 0,08
Fasting glucose, mmol/l 5,3 (4,9;5,7) 5,5 (5,2;6,1) 5,6 (5,3;6,5)# 5,7 (5,2;6,5)# 0,046
НОМА index 0,9 (0,6;1,2) 1,5 (1,2;2,2)## 2,3 (1,6;3,1)##† 3,2 (2,2;4,5)##††§ 0,0001
MS, % 15,4 25,7 37,1# 55,6##† 0,0005
Women n = 44 n = 45 n = 44 n = 44
Age, years 49,1 ± 11,1 49,8 ± 8,9 51,6 ± 8,9 50,6 ± 7,2 0,5
BMI kg/m2 23,6 ± 3,8 26,8 ± 2,8## 29,5 ± 3,6##† 33,3 ± 5,2##††§§ 0,0001
WC, cm 78,7 ± 9,5 87,4 ± 8,0## 92,1 ± 8,7##† 97,5 ± 9,9##††§ 0,0001
AH, n (%) 11 (25) 13 (29,5) 23 (51,1)# 20 (45,5) 0,01
SBP, mm Hg 127 ± 20 128 ± 21 140 ± 23##† 136 ± 19† 0,001
DBP, mm Hg 81 ± 10 82 ± 11 88 ± 12##† 86 ± 11 0,003
TC, mmol/l 4,8 ± 1,1 5,0 ± 0,9 5,1 ± 1,2 4,9 ± 0,9 0,7
TG, mmol/l 0,9 (0,7;1,3) 1,2 (0,9;1,4) 1,2 (0,9;1,8)# 1,1 (1,0;1,5)# 0,05
HDL-C, mmol/l 1,3 ± 0,4 1,2 ± 0,3 1,1 ± 0,3 1,2 ± 0,3 0,2
LDL-C, mmol/l 2,9 ± 0,9 3,2 ± 0,9 3,2 ± 1,0 3,2 ± 0,8 0,5
Type 2 DM, n (%) 3 (6,8) 3 (6,8) 1 (2,2) 1 (2,3) 0,5
Fasting glucose, mmol/l 5,2 (4,9;5,5) 5,5 (5,1;5,8)# 5,5 (5,2;6,3)# 5,6 (5,3;6,0)## 0,001
НОМА index 0,9 (0,8;1,4) 1,8 (1,4;2,6)## 2,3 (1,6;3,6)## 2,7 (2,1;4,0)##†† 0,0001
MS, % 15,9 17,8 50## † 50## † 0,00005
*- quartile of leptine: men (< 2,2; 2,2-4,2; 4,3-6,34; > 6,34), women (< 8,05; 8,05-13,4; 13,5- 19,09; 19,09).
#- p < 0,05; ## - p < 0,001 compared to the first quartile.
†- p < 0,05; ††- p < 0,001 compared to the second quartile.
§- p < 0,05; §§ - p < 0,001 compared to the third quartile.
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[28]. Different studies revealed an association between
leptin and regional adiposity. Leptin is more dependent on
subcutaneous adipose tissue than on abdominal visceral
tissue [29], since subcutaneous adipocytes secrete more
leptin than omental fat tissue [30]. Studies have shownTable 3 Leptin levels and BMI
BMI kg/m2 n Men (n = 145) n Women (n = 177)
< 25 47 2,0 (1,4; 3,5) 45 6,3 (3,9; 8,5)
25-29,9 71 4,8 (3,2; 6,2) 65 13,3 (10,5; 17,2)
≥ 30 27 8,0 (5,7; 12,7)* 67 18,87 (15,7; 24,7)*
*- p < 0,001.higher subcutaneous fat content in women than in men
[31-33]. It is known that leptin levels reflect the amount of
adipose tissue in the body, and hyperleptinemia is com-
mon in general and abdominal obesity. Similar results
were obtained in the present study: serum leptin levels
were significantly associated with abdominal obesity
(AO), hypertriglyceridemia, and hyperglycemia. In addition,
serum leptin levels positively correlated with BMI in pa-
tients of both sexes, although women had a higher BMI.
The results of research on the relationship between serum
leptin and lipids showed conflicting data. Some studies re-
vealed no relationship between leptin and the parameters
of a lipid profile [34,35]. Other studies showed a significant
positive correlation between leptin and HDL-C [36,37] and























Low physical activity* 1,43 0,003
Women:
Leptin 1,93 0,000






*Low physical activity – less than 30 min a day.
Table 4 The Spearman correlation coefficient between
leptin and independent factors
Men Women
r P r p
Age −0,063 0,45 0,127 0,09
BMI kg/m2 0,719 0,000 0,74 0,000
WC, cm 0,684 0,000 0,649 0,000
HC, cm 0,659 0,000 0,621 0,000
WC/HC 0,341 0,000 0,243 0,001
TC, mmol/l 0,214 0,01 0,09 0,235
TG, mmol/l 0,301 0,000 0,194 0,01
HDL-C, mmol/l −0,079 0,3 −0,156 0,04
LDL-C, mmol/l 0,163 0,05 0,126 0,09
Fasting glucose, mmol/l 0,256 0,002 0,306 0,000
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ation of leptin with TC in men and a weak negative correl-
ation with HDL-C in women, probably due to the higher
prevalence of hypercholesterolemia and decreased HDL-C
in men and in women, respectively. At the same time, lep-
tin levels were significantly correlated with TG in patients
of both sexes. TG is stored in adipose tissue as the main
form of energy among the biochemical markers, which ex-
plains its correlation with leptin [39-41].
In our study, we found an association of leptin with AH,
which was confirmed in other studies such as the Olivetti
Heart Study [42]. The prehypertensive effect of leptin
was also shown in experimental animal research [43-46].
Apparently, such a relationship of leptin with AH is asso-
ciated with the sympathetic nervous system, and its activa-
tion accompanies obesity in humans [47,48]. In our study,clusion of the variables: obesity, AH, IR и DM
Expected ß 95% CI expected ß
- obesity
30,8 7,3 - 129,6
0,031 0,002 - 0,39
0,123 0,03 - 1,21
17,71 6,64 – 47,2
0,24 0,07 – 0,87
3,17 1,18 – 8,54
t – АH
1,054 1,01 – 1,096
1,24 1,12 – 1,38
2,99 1,2 – 7,44
1,097 1,05 – 1,15
1,12 1,04 – 1,2
nt– IR
4,25 2,14 – 8,43
0,096 0,02 – 0,51





5,16 1,01 – 26,4
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leptinemia and AH, which disappeared after adjustment
for BMI as an independent variable, indicating a relation-
ship with obesity. Indeed, the physiological influence
of leptin is shown in weight loss as reduced appetite and
increased energy expenditure, as a result of the central
stimulating effect on the activity of the sympathetic ner-
vous system [49]. The kidneys are involved in the process.
Studies have shown a clear association between circulating
leptin levels and enhanced renal sympathetic stimulation
[50], which was accompanied under experimental condi-
tions by increased secretion of renin, and enhanced so-
dium and water reabsorption in the proximal tubule [51].
Despite that, the association between AH and obesity may
be explained by the presence of IR and hyperinsulinemia
[52]. In this study, we have shown a statistically signifi-
cant association between blood leptin levels and IR in
both men and women.
However, it is important to note that genetic factors
influences the metabolism of leptin. For example, the 3’
UTR and Gln223Arg polymorphism of the leptin recep-
tor were shown to play a role in the development of
hyperleptinemia and AH [53,54]. Furthermore, impair-
ment of β adrenergic receptor function, as well as G pro-
tein and calcium/calmodulin-dependent kinase IV play a
role in the development of IR [21,55-57]. Unfortunately,
we were unable to investigate the role of those genes in
our study.
Conclusion
Obviously, leptin as a biomarker for body fat reflects a
yet unexplored activity of adipocytes and can provide
important information regarding the risk of cardiovascu-
lar disease [58]. The results of our study show that leptin
is associated with general and abdominal obesity, dyslipid-
emia, and IR. At the same time, further large-scale pro-
spective studies are in great demand to better understand
and closely investigate the physiological and pathological
functions of leptin.Abbreviations
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